DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on August 14, 2008; DOI: 10.1124/dmd.108.021642


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.108.021642v1
36/11/2393    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Author home page(s):
James M. Fujitaki
Edward E. Cable
Bruce R. Ito
Bao-Hong Zhang
Jinzhao Hou
Chun Yang
David A. Bullough
James L. Ferrero
Paul D. van Poelje
David L. Linemeyer
Mark D. Erion
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fujitaki, J. M.
Right arrow Articles by Erion, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fujitaki, J. M.
Right arrow Articles by Erion, M. D.


Received for publication March 27, 2008.
Revised August 8, 2008.
Accepted for publication August 12, 2008.

Preclinical Pharmacokinetics of a HepDirect Prodrug of a Novel Phosphonate-Containing Thyroid Hormone Receptor Agonist

James M. Fujitaki 1*, Edward E. Cable 1, Bruce R. Ito 1, Bao-Hong Zhang 1, Jinzhao Hou 1, Chun Yang 1, David A. Bullough 1, James L. Ferrero 1, Paul D. van Poelje 1, David L. Linemeyer 1, Mark D. Erion 1

1 Metabasis Therapeutics, Inc.

* Address correspondence to: E-mail: fujitaki{at}mbasis.com

Abstract

The prodrug (MB07811) of a novel phosphonate-containing thyroid hormone receptor (TR) agonist (MB07344) is the first application of the HepDirect1 liver-targeting approach to a non-nucleotide agent. The disposition of MB07811 was characterized in rat, dog, and monkey to assess its liver-specificity which is essential in limiting the extrahepatic side effects associated with this class of lipid lowering agents. MB07811 was converted to MB07344 in liver microsomes from all species tested (CLint 1.23-145.4 µL/min/mg). The plasma clearance and volume of distribution of MB07811 matched or exceeded 1 L/h/kg and 3 L/kg, respectively. Although absorption of prodrug was good, its absolute oral bioavailability as measured systemically was low (3-10%), an indication of an extensive hepatic first pass effect. This effect was confirmed by comparison of systemic exposure levels of MB07811 following portal and jugular vein administration to rats, which demonstrated a hepatic extraction ratio of >0.6 with liver CYP3A-mediated conversion to MB07344 a major component. The main route of elimination of MB07811 and MB07344 was biliary, with no evidence for enterohepatic recirculation of MB07344. Similar metabolic profiles of MB07811 were obtained in liver microsomes across the species tested. Tissue distribution and whole body autoradiography confirmed that liver is the major target organ of MB07811 and that conversion to MB07344 was high in the liver relative to other tissues. Hepatic first pass extraction and metabolism of MB07811, coupled with likely selective distribution of MB07811-derived MB07344, led to a high degree of liver targeting of MB07344.


Key words: biliary excretion, CYP3A, drug disposition, drug targeting, first-pass metabolism, hepatobiliary disposition, liver microsomes, oral absorption, pharmacokinetics, prodrugs





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.